Glen Rock, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (œRespireRx or the œCompany), focused on the discovery and development of innovative and...
Enforcement Report for Week of June 28, 2023
The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Dronabinol Capsules
The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Dronabinol Capsules, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules, 20 mg Due to Label Mix-up
The CBD and THC market is growing rapidly, and many people throughout the United States are now exploring their options to see if they can find a product worth their time. While there is already an abundance of standout CBD and THC products on the market, such as edibles, tinctures, and lotions, customers can now purchase disposable vape pens containing the psychoactive cannabinoid Delta-8 Tetrahydrocannabinol, also known as Delta-8 THC.
Each of these new therapies has a proposed rationale for its utility. Ketamine and its molecular sister esketamine increase the effect of glutamate, the most widespread natural chemical stimulant in the brain. Cannabis binds to a series of receptors for its active ingredients, tetrahydrocannabinol and cannabidiol existent in the brain.
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Sleep Review Magazine has published, in its June 13, 2022 edition, a free e-book entitled “How Close Are We to Drug Therapy for Obstructive Sleep Apnea?”, in which it discusses the RespireRx dronabinol OSA program as one of four emerging drug treatments for the treatment of OSA.
BURLINGTON, ON, June 7, 2021 /CNW/ - EmpowerPharm today announced they have been certified to manufacture products containing cannabidiol (CBD) to prescription drug standards – a Canadian first.
Researchers examine the effectiveness of consuming hemp oil extracted from the whole Cannabis plant using a chronic neuropathic pain animal model. Researchers at The University of New Mexico (UNM) showed that legal Cannabis hemp oil reduced mechanical pain sensitivity 10-fold for several hours in mice with chronic post-operative neuropathic pain.
BERLIN, April 27, 2020 /PRNewswire/ -- Since 15 April 2020, German pharmacies have been able to purchase the active ingredient dronabinol (also known as tetrahydrocannabinol or THC) directly from Cantourage – the new supplier of dronabinol, which is pure THC as an API (active pharmaceutical ingredient). Cantourage is therefore also helping to improve the supply situation in times of Corona. Dronabinol represents roughly 30% turnover of the overall medicinal cannabis market in Europe. Canopy Growth has acquired the dronabinol business of Bionorica in 2019 for 226 MEUR* and is now being challenged by the new competition with the best value proposition for pharmacies in Germany and Europe. Cantourage has its own exclusive production relationship with Israeli cannabis producer BOL (Breath of Life) Pharma for dronabinol, which pharmacies use to make patient-specific drugs. Cantourage was established by the former founders of Pedanios, Dr. Florian Holzapfel and Patrick Hoffmann, together with Norman Ruchholtz. In the past, they developed Pedanios into the European market leader for cannabis flowers and have sold Pedanios in 2017 to Aurora Cannabis. At Cantourage, they are now continuing the success story of medical cannabis in Europe and offer a new service for companies outside Europe.